Market Research Logo

North America Opioid Market Analysis By Product (Immediate-release/Short-acting, Extended-release/Long-acting, Codeine, Oxycodone, Hydrocodone, Fentanyl, Morphine, Hydroxymorphone, Oxymorphone, Propoxyphene, Methadone, Tapentadol, Buprenorphine), By Appli

North America Opioid Market Analysis By Product (Immediate-release/Short-acting, Extended-release/Long-acting, Codeine, Oxycodone, Hydrocodone, Fentanyl, Morphine, Hydroxymorphone, Oxymorphone, Propoxyphene, Methadone, Tapentadol, Buprenorphine), By Application (Pain Relief, Cancer Pain, Post-operative Pain Management, Low Back Pain, Orthopedic, Anesthesia, Neuropathic Pain, Fibromyalgia, Cough Suppression, Diarrhoea Suppression, De-addiction) And Segment Forecasts To 2024

The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, conducive for research and development as well as commercialization efforts directed toward the development of novel abuse-deterrent opioids, to flourish and drive the industry growth during the forecast period. Furthermore, the key players are deploying large funds in the development of abuse-deterrent technology wherein drugs are designed to be tamper resistant. This is achieved through alterations involving, among others, the use of physical or chemical barriers to resist convenient extraction of the opioids, the addition of an aversive agent to the formulation that would yield an unpleasant effect upon its extraction, and the formulation of opioid prodrugs that are dependent on enzymatic activity in order to be rendered to their active forms. These tamper-resistant opioid drug forms are anticipated to mitigate the incidence of their misuse.

Opioids are the mainstay of chronic pain management that is used to alleviate varied pain conditions. Opiates including codeine and morphine are frequently employed as cough suppression medication. Codeine is considered as a gold standard for cough suppression since it has minimal side effects. Moreover, these narcoticsare used in the treatment of irritable bowel syndrome-induced diarrhea since they act on gastrointestinal receptors. In addition, peripherally acting loperamide is commonly used to suppress diarrhea. Thus, theprofitable growth of the Opioid Market lies in its breadth of applications in the management of diverse conditions including cough, diarrhea, and pain.

Further key findings from the study suggest:

The extended-release opioids segment accounted for the largest share over 55% in 2015. The dominance of the segment is attributed to the high usage of these drugs for chronic pain management and the development of innovative dosage forms, such as transdermal patches.

Market share of the immediate-release dosage formsincluding morphine and codeine, is expected to decline owing to the frequent product recalls and severe side effects associated with their use. The segment is estimated to witness a CAGR of around 1.7% over the forecast period.

In terms of applications, the pain relief segment held the largest market share in 2015 with a revenue generation of over 9.3 billion. The extensive amount of pain caused during chemotherapy and radiotherapy are the primary factors resulting in the increasing incorporation of these drugs in the cancer segment.

The post-operative pain management segment is expected to be the fastest growing application in the pain relief category.As a result of their high applicability in post- surgical pain management, the rise in number of surgical procedures is expected to fuel the sectorpenetration of opioids in the near future.

The U.S. region dominated the global Opioid Market with a sizable revenue share in 2015. One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.

In addition, the increasing adoption of opioids for pain management related to trauma and injury cases, in severe and chronic disabling diseases, and in cases of post-surgical pain, is driving the growth of the market in the North America region

The Canada regional verticalis expected to witnesssignificant growth over the forecast period with a CAGR of over 5.3% due tothe improvinghealthcare infrastructure and the presence of favorable government reforms governing the use of narcoticsin the treatment of both, acute and chronic pain, as well as in the cases of persistent cough and diarrhea. Additionally, the expanding generic drugs market in this region is expected to provide a potential growth platform for the key players in this vertical.

Some of the leadingplayers in this verticalinclude Pfizer, Inc., Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., Allergan Plc (Actavis), and Egalet Corporation. Extensive research and development endeavors carried out by companies with the aim of expanding their product pipeline are expected to boost the growth of this sector.


Chapter 1 Research Methodology
1.1 Research Methodology
1.2 Research Scope & Assumptions
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
4.1 Market segmentation & scope
4.1.1 Market Driver Analysis
4.1.1.1 Expanding applications of opioids in various therapeutic conditions
4.1.1.2 Expanding target audience for the Opioid Market
4.1.1.3 Formulation of opioids switching from immediate to extended - release forms
4.1.1.4 Lack of control over opioid prescription abuse in Canada
4.1.2 Restraint analysis
4.1.2.1 Stringent regulatory framework
4.1.2.2 Opioid abuse and dependency
4.2 North America Opioid Market - SWOT Analysis, By Factor (political & legal, economic and technological)
4.3 Industry Analysis - Porter’s
Chapter 5 Market Categorization 1: Product Estimates & Trend Analysis
5.1 North America Opioid Market: Product movement analysis
5.2 Immediate - release/Short - acting opioids
5.2.1 Immediate - release/Short - acting opioidsmarket, 2013 - 2024 (USD Million)
5.2.2 Codeine market, 2013 - 2024 (USD Million)
5.2.3 Oxycodone market, 2013 - 2024 (USD Million)
5.2.4 Hydrocodone market, 2013 - 2024 (USD Million)
5.2.5 Fentanyl market, 2012 - 2024 (USD Million)
5.2.6 Morphine market, 2013 - 2024 (USD Million)
5.2.7 Hydroxymorphone market, 2013 - 2024 (USD Million)
5.2.8 Oxymorphone market, 2013 - 2024 (USD Million)
5.2.9 Propoxyphene market, 2013 - 2024 (USD Million)
5.2.10 Other IR Opioid Market, 2013 - 2024 (USD Million)
5.3 Extended - release/Long - acting opioids
5.3.1 Extended - release/Long - acting Opioid Market, 2013 - 2024 (USD Million)
5.3.2 Oxycodone market, 2013 - 2024 (USD Million)
5.3.3 Hydrocodone market, 2013 - 2024 (USD Million)
5.3.4 Methadone market, 2013 - 2024 (USD Million)
5.3.5 Fentanyl market, 2013 - 2024 (USD Million)
5.3.6 Morphine market, 2013 - 2024 (USD Million)
5.3.7 Oxymorphone market, 2012 - 2024 (USD Million)
5.3.8 Tapentadol market, 2013 - 2024 (USD Million)
5.3.9 Buprenorphine market, 2013 - 2024 (USD Million)
5.3.10 Hydromorphone market, 2013 - 2024 (USD Million)
5.3.11 Others market, 2012 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Application Estimates & Trend Analysis
6.1 Pain Relief
6.1.1 Pain relief market, 2013 - 2024 (USD Million)
6.1.2 Cancer pain market, 2013 - 2024 (USD Million)
6.1.3 Post - operative care market, 2013 - 2024 (USD Million)
6.1.4 Lower back pain market, 2012 - 2024 (USD Million)
6.1.5 Orthopedic market, 2013 - 2024 (USD Million)
6.1.6 Neuropathic market, 2013 - 2024 (USD Million)
6.1.7 Fibromyalgia market, 2013 - 2024 (USD Million)
6.2 Anesthesia
6.2.1 Anesthesia market, 2013 - 2024 (USD Million)
6.3 Cough Suppression
6.3.1 Cough Suppression, 2013 - 2024 (USD Million)
6.4 Diarrhea suppression
6.5 De - addiction
Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Product & Application
7.1 North America Opioid Market share, by region, 2015 & 2024
7.1.1 North America Opioid Market, 2013 - 2024 (USD Million)
7.1.2 U.S.opioidsmarket, 2013 - 2024 (USD Million)
7.1.3 Canadaopioidsmarket, 2013 - 2024 (USD Million)
Chapter 8 Competitive Landscape
8.1 Company Profiles
8.1.1 Purdue Pharma L.P.
8.1.1.1 Company Overview
8.1.1.2 Financial Performance
8.1.1.3 Product Benchmarking
8.1.1.4 Strategic Initiatives
8.1.2 Egalet Corporation
8.1.2.1 Company Overview
8.1.2.1 Financial Performance
8.1.2.2 Product Benchmarking
8.1.2.3 Strategic Initiatives
8.1.3 Janssen Pharmaceuticals, Inc.
8.1.3.1 Company Overview
8.1.3.1 Financial Performance
8.1.3.2 Product Benchmarking
8.1.3.3 Strategic Initiatives
8.1.4 West - Ward Pharmaceuticals Corporation
8.1.4.1 Company Overview
8.1.4.1 Financial Performance
8.1.4.2 Product Benchmarking
8.1.4.3 Strategic Initiatives
8.1.5 Pfizer,Inc.
8.1.5.1 Company Overview
8.1.5.1 Financial Performance
8.1.5.2 Product Benchmarking
8.1.5.3 Strategic Initiatives
8.1.6 Allergan Plc (Actavis)
8.1.6.1 Company Overview
8.1.6.1 Financial Performance
8.1.6.2 Product Benchmarking
8.1.6.3 Strategic Initiatives
8.1.7 Sanofi - Aventis S.A.
8.1.7.1 Company Overview
8.1.7.1 Financial Performance
8.1.7.2 Product Benchmarking
8.1.7.3 Strategic Initiatives
8.1.8 Sun Pharmaceutical Industries Limited
8.1.8.1 Company Overview
8.1.8.1 Financial Performance
8.1.8.2 Product Benchmarking
8.1.8.3 Strategic Initiatives
List of Tables
TABLE 1 North America Immediate - release(IR) Opioid Market: Drug information
TABLE 2 North America extended - release(ER)/long - acting Opioid Market: Drug Information
TABLE 3 North America Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 4 North America IR Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 5 North America ER Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 6 North America Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 7 North America pain relief Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 8 U.S. Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 9 U.S. IR Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 10 U.S. ER Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 11 U.S. Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 12 U.S. pain relief Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 13 Canada Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 14 Canada IR Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 15 Canada ER Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 16 Canada Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 17 Canada pain relief Opioid Market, by application, 2013 - 2024 (USD Million)
List of Figures
FIG. 1 Market summary, 2015 (USD million)
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 SWOT Analysis
FIG. 5 Porter’s Five Forces Analysis
FIG. 6 North America Immediate - release/Short - acting Opioid Market, 2012 - 2024 (USD Million)
FIG. 7 North America codeine market, 2013 - 2024 (USD Million)
FIG. 8 North America oxycodone market, 2013 - 2024 (USD Million)
FIG. 9 North America hydrocodone market, 2013 - 2024 (USD Million)
FIG. 10 North America fentanyl market, 2013 - 2024 (USD Million)
FIG. 11 North America morphine market, 2013 - 2024 (USD Million)
FIG. 12 North America hydroxymorphone market, 2013 - 2024 (USD Million)
FIG. 13 North America oxymorphone market, 2012 - 2024 (USD Million)
FIG. 14 North America propoxyphene market, 2013 - 2024 (USD Million)
FIG. 15 North America other IR Opioid Market, 2013 - 2024 (USD Million)
FIG. 16 North America extended - release/long - acting Opioid Market, 2013 - 2024 (USD Million)
FIG. 17 North America oxycodone market, 2013 - 2024 (USD Million)
FIG. 18 North America hydrocodone market, 2013 - 2024 (USD Million)
FIG. 19 North America methadone market, 2013 - 2024 (USD Million)
FIG. 20 North America fentanyl market, 2013 - 2024 (USD Million)
FIG. 21 North America morphine market, 2013 - 2024 (USD Million)
FIG. 22 North America oxymorphone market, 2013 - 2024 (USD Million)
FIG. 23 North America tapentadol market, 2013 - 2024 (USD Million)
FIG. 24 North America buprenorphine market, 2013 - 2024 (USD Million)
FIG. 25 North America hydromorphone market, 2013 - 2024 (USD Million)
FIG. 26 Other ER market, 2013 - 2024 (USD Million)
FIG. 27 Pain relief market, 2013 - 2024 (USD Million)
FIG. 28 Cancer pain market, 2013 - 2024 (USD Million)
FIG. 29 Post - operative pain management market, 2013 - 2024 (USD Million)
FIG. 30 Low back pain market, 2013 - 2024 (USD Million)
FIG. 31 Orthopedic market, 2013 - 2024 (USD Million)
FIG. 32 Neuropathic market, 2013 - 2024 (USD Million)
FIG. 33 Fibromyalgia market, 2013 - 2024 (USD Million)
FIG. 34 Anesthesia market, 2013 - 2024 (USD Million)
FIG. 35 Cough Suppression market, 2013 - 2024 (USD Million)
FIG. 36 Diarrhoea suppression market, 2013 - 2024 (USD Million)
FIG. 37 De - addiction market, 2013 - 2024 (USD Million)
FIG. 38 North America Opioid Market, 2013 - 2024 (USD Million)
FIG. 39 U.S. Opioid Market, 2013 - 2024 (USD Million)
FIG. 40 Canada pain reliever usage rates, 2009 - 2013 (Percentage)
FIG. 41 Canada Opioid Market, 2013 - 2024 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report